

OVERVIEW

Stem Cell Therapeutics Corp (TSX-V: SSS) is a Canadian clinical and developmental stage biotechnology company using drugs to stimulate proliferation and differentiation of endogenous adult stem cells in the brain to treat a variety of neurological disorders; including acute ischemic stroke, traumatic brain injury and multiple sclerosis.

H1
10
FACT
SHEET

BUILDING THE LEADING PRODUCT BASED NEUROLOGICAL COMPANY

WWW.STEMCELLTHERA.COM

CORPORATE HISTORY

SCT was incorporated in March 2004 based on stem cell pharmacology patents acquired from Dr. Samuel Weiss, Director of Hotchkiss Brain Institute at the University of Calgary, and Transition Therapeutics Inc. (TSX: TTH; NASDAQ: TTHI).

FINANCING HISTORY

- January 2005 IPO at \$0.25 per share, raised \$8.5 million
- Two \$2.0 million non-brokered Private Placements in 2007: (1) in January at \$0.20 per share & (2) in March at \$0.50 per share
- November 2007 closed \$12.075 million Bought Deal at \$0.35 per share; led by Dundee Securities
- October 2009 closed \$2.19 million Private Placement at \$0.12; led by J.F.Mackie & Co.

TARGET THERAPEUTIC AREAS

Acute Ischemic Stroke

- Major unfilled need;
- Only one available therapy (clot-busting drug tPA) used in less than 5% of patients;
- Leading cause of long-term physical and mental disability;
- 15 million strokes worldwide annually, of these 5 million die and 5 million are left permanently disabled.

Traumatic Brain Injury ("TBI")

- Major unfilled need;
- No effective long term therapy;
- 10 million survivors worldwide; 5.3 million in the U.S. living with TBI related disabilities.

Multiple Sclerosis ("MS")

- Progressive degenerative disease;
- Present therapy is ineffective in stopping/reversing disease progression;
- 2.5 million patients worldwide.

2010 MILESTONES

STROKE

- Q1 10 Complete enrollment in modified REGENESIS Phase IIb acute ischemic stroke study
- Q2 10 Report Top-line REGENESIS Phase IIb data
- H2 10 Complete preclinical study for hemorrhagic stroke
- H2 10 Complete 'end of Phase II' meeting with FDA prior to initiation of Phase III program

TRAUMATIC BRAIN INJURY

- H1 10 Initiate and enroll patients in a Phase IIa TBI clinical study

MULTIPLE SCLEROSIS

- H2 10 Initiate MS clinical Proof-of-Concept study

OVERALL

Actively seek partnerships for individual or multiple programs

PRODUCT PIPELINE

| CURRENT CLINICAL STATUS | DISEASE INDICATION | R&D | PRE-CLINICAL | PHASE I | PHASE II | PHASE III |
|-------------------------|------------------------|-----------|--------------|---------|----------|-----------|
| NTx®-265 | Stroke -ischemic | ENROLLING | | | | |
| NTx®-428 | Traumatic Brain Injury | | | | | |
| NTx®-488 | Multiple Sclerosis | | | | | |

TSX-VENTURE: SSS

TECHNOLOGY

SCT's lead therapy, NTx[®]-265, of human Chorionic Gonadotropin ("hCG") and Erythropoietin ("EPO") is used to treat both acute ischemic stroke and TBI. It works by stimulating endogenous 'in house' adult stem cells in the patient's brain to first proliferate (hCG) and then differentiate (EPO) into new neural tissue to replace the brain cells that were lost or damaged by the stroke, and importantly, to direct motor, visual and cognitive recovery after acute ischemic stroke.

Prolactin is being developed to treat MS as it activates endogenous oligodendrocyte precursor cells ("OPC") which in turn re-form the myelin sheath on the outside of the nerve that is lost during the disease. Prolactin also increases neural stem cell proliferation and neuron formation and thereby repairs the neuronal damage in MS, which is necessary for full functional recovery.

CURRENT STATUS

Stroke: Phase IIb double-blind, placebo controlled, 128 patient stroke study is in progress.

TBI: Small Phase IIa TBI study in final stages of regulatory submission.

MS: Phase IIb double-blind, placebo controlled, study of prolactin in MS is scheduled to begin recruiting in H2 10.

SUPPORTIVE DATA

- Data from key animal models support drug activity in each therapeutic area of acute ischemic stroke, TBI and MS.
- Encouraging final clinical results from BETAS (Beta-hCG + Erythropoietin in Acute Stroke) Phase IIa stroke trial showed clinically relevant recovery in 12 of 12 patients who received the complete treatment.
- Meta-analysis of the total stroke patient data base from BETAS Phase IIa and REGENESIS Phase IIb (7 patients before clinical hold), comprising of 5 placebo (non-drug) treated patients and 14 NTx[®]-265 treated patients (12 from BETAS and 2 from REGENESIS) that showed a $p < 0.0001$ highly significant beneficial effect of the drug-treatment on the stroke patients recovery. Patients were tested using the NIH stroke scale which is the standard method of measuring neurological function in stroke patients. Additionally, several patients received an MRI "before" and "after" treatment, those treated with NTx[®]-265 showed a clear overall reduction of infarct (damaged brain tissue) size over a 90-day period.

MARKET DATA

(as at January 29, 2010; in Canadian Dollars)

| | |
|---------------------------|---------------|
| TSX-Venture symbol | SSS |
| Stock Price | \$0.345 |
| Common Shares Outstanding | 152.9 Million |
| Cash-on-hand | \$4.4 Million |

MANAGEMENT AND ADVISORS

MANAGEMENT TEAM:

Dr. Alan Moore, PhD
President & CEO

Mr. Barry Herring, CA
VP, Finance & CFO

Mr. Thomas Franck
VP, Commercial Planning

Dr. Allen Davidoff, PhD
VP, Product Development

BOARD OF DIRECTORS

Mr. Ian Brown, BA, BComm, CA
Independent Businessman

Dr. James DeMesa, MD
Biotechnology Executive & Consultant

Dr. Alan Moore, PhD
President & CEO

Mr. Robert Rieder, MBA

Executive Chairman, Cardiome Pharma Corp.
(NASDAQ: CRME, TSX: COM)

Mr. Scott Tannas

Founder, President & CEO,
Western Financial Group (TSX: WES)

Mr. Mark Wayne, LLB, CFA
VP, MGI Securities Inc.

CLINICAL ADVISORY BOARD:

Dr. Steven Cramer, MD
University of California, Irvine, USA

Dr. Michael Hill, MD
University of Calgary, Canada

Dr. Hannelore Ehrenreich, DVM, MD
Max-Planck-Institute of Experimental
Medicine, Göttingen, Germany.

SCIENTIFIC ADVISORY BOARD:

Dr. W. Dalton Dietrich III, PhD
Scientific Director, The Miami Project
to Cure Paralysis, Miami, Florida

Dr. Myron Ginsberg, MD
Neurotrauma Research Center,
University of Miami/Jackson Memorial
Medical Center, Miami, Florida

Dr. Joshua Hare, MD
Miller School of Medicine,
University of Miami, Miami, Florida

Dr. Craig Pratt, MD
Methodist DeBakey Heart Center,
Methodist Hospital, Houston, Texas

Dr. Samuel Weiss, PhD
Hotchkiss Brain Institute,
University of Calgary, Faculty of Medicine,
Calgary, Alberta

STEM CELL THERAPEUTICS

HEAD OFFICE

Stem Cell Therapeutics Corp.
Suite 1000, 1520 - 4th Street SW
Calgary, Alberta, Canada T2R 1H5
Phone: 403.245.5495
Fax: 403.245.5411

www.stemcellthera.com

INVESTOR RELATIONS

Chloe Douglas-Crampton
Manager, Investor Relations
Phone: 403.245.5495, ext. 221
crampton@stemcellthera.com

This fact sheet contains statements about expected future events and financial and operation results that are forward-looking and subject to risk and uncertainties. Actual results, performance, or achievements could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Stem Cell Therapeutics Corp. disclaims any intention or obligation to update or revise any existing or forward-looking statements, whether as a result of new information, future events or otherwise.